Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Vanda Pharmaceuticals Inc.
Healthcare
P/NCAV
0.81x
Ticker
VNDA
Exchange
NASDAQ
Country
United States
Close
4.63 $
Mkt Cap
266.5M $
EV
130.7M $
NCAV Burn Rate
20.1%
Current Ratio
4.94
Debt/Equity
0.0
EV/REV
0.68x
EV/EBIT
-9.4x
EV/FCF
9.9x
Dilution
5.1% p.A
Total Net Income
152.8M $
Cheapness
97.0%
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn-s disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average